BI Asset Management Fondsmaeglerselskab A S Has $399,000 Stock Holdings in West Pharmaceutical Services, Inc. $WST

BI Asset Management Fondsmaeglerselskab A S reduced its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 69.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,592 shares of the medical instruments supplier’s stock after selling 3,623 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in West Pharmaceutical Services were worth $399,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Empowered Funds LLC boosted its position in West Pharmaceutical Services by 16.1% during the 1st quarter. Empowered Funds LLC now owns 1,611 shares of the medical instruments supplier’s stock worth $361,000 after buying an additional 224 shares during the period. Intech Investment Management LLC grew its holdings in West Pharmaceutical Services by 27.7% during the 1st quarter. Intech Investment Management LLC now owns 6,020 shares of the medical instruments supplier’s stock worth $1,348,000 after acquiring an additional 1,307 shares during the last quarter. Acadian Asset Management LLC increased its position in West Pharmaceutical Services by 14.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,271 shares of the medical instruments supplier’s stock valued at $284,000 after acquiring an additional 157 shares during the period. EverSource Wealth Advisors LLC increased its position in West Pharmaceutical Services by 78.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 449 shares of the medical instruments supplier’s stock valued at $98,000 after acquiring an additional 197 shares during the period. Finally, First Trust Advisors LP raised its stake in shares of West Pharmaceutical Services by 168.4% during the second quarter. First Trust Advisors LP now owns 46,332 shares of the medical instruments supplier’s stock valued at $10,137,000 after acquiring an additional 29,067 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

Insiders Place Their Bets

In other news, CAO Chad Winters sold 896 shares of West Pharmaceutical Services stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $300.67, for a total value of $269,400.32. Following the completion of the transaction, the chief accounting officer directly owned 1,523 shares of the company’s stock, valued at approximately $457,920.41. This trade represents a 37.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Annette F. Favorite sold 2,817 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the transaction, the vice president directly owned 16,828 shares in the company, valued at $5,135,905.60. This represents a 14.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.60% of the company’s stock.

West Pharmaceutical Services Stock Up 2.0%

Shares of NYSE WST opened at $347.34 on Friday. The company has a market capitalization of $24.54 billion, a P/E ratio of 46.44, a price-to-earnings-growth ratio of 2.85 and a beta of 1.18. West Pharmaceutical Services, Inc. has a 52-week low of $206.80 and a 52-week high of $352.31. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71. The company’s 50 day moving average price is $312.15 and its 200-day moving average price is $275.06.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.45. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The company had revenue of $844.90 million during the quarter, compared to analysts’ expectations of $779.67 million. During the same period in the prior year, the company posted $1.45 earnings per share. West Pharmaceutical Services’s revenue for the quarter was up 21.0% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Equities analysts forecast that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on WST shares. Zacks Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Citigroup restated a “buy” rating on shares of West Pharmaceutical Services in a report on Friday, April 24th. Barclays raised West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $310.00 to $400.00 in a research report on Tuesday, June 9th. Weiss Ratings raised West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, April 27th. Finally, Wolfe Research began coverage on West Pharmaceutical Services in a research report on Monday, June 1st. They issued an “outperform” rating and a $375.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, West Pharmaceutical Services presently has a consensus rating of “Buy” and a consensus price target of $340.09.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.